+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Jakafi"

From
From
Post-Polycythemia Vera Myelofibrosis - Pipeline Insight, 2024 - Product Thumbnail Image

Post-Polycythemia Vera Myelofibrosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
JAKAFI Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

JAKAFI Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
JAKAFI Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

JAKAFI Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Jakafi (ruxolitinib) is a hematological drug used to treat myelofibrosis and polycythemia vera, two rare bone marrow diseases. It is a Janus kinase (JAK) inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Jakafi is the first and only FDA-approved JAK inhibitor for the treatment of these diseases. It is available in both oral and intravenous forms. Jakafi is a relatively new drug, having been approved by the FDA in 2011. Since then, it has become a popular treatment option for patients with myelofibrosis and polycythemia vera. It has been shown to reduce symptoms, improve quality of life, and even prolong survival in some cases. The Jakafi market is highly competitive, with several companies offering their own versions of the drug. These include Incyte Corporation, Novartis, and Pfizer. Other companies, such as Celgene and Gilead Sciences, are also developing their own JAK inhibitors for the treatment of these diseases. Show Less Read more